Zirconium (89Zr) girentuximabum senvedoxamum

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights 1 Group revenue of US$247 million, up 7% quarter-over-quarter (QoQ) and up 21% year-over-year (YoY). Precision Medicine continues to deliver strong growth, revenue of US$202 million, up 9% QoQ and up 30% YoY. Telix expects FY 2026 revenue and other income to be in excess of US$1 billion, with revenue tracking in line with the upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million non-refundable other income received from Regeneron. United States (U.S.) Food and Drug Administration (FDA) alignment on ProstACT Global Phase 3 study of TLX591-Tx in mCRPC 2 to advance to Part 2 in the U.S. 3 BiPASS™, patient enrollment nearing completion for study of Illuccix ® and Gozellix ® for initial prostate cancer diagnosis in the pre-biopsy setting 4 . Regeneron strategic collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies, initially focused on lung cancer. FY 2026 research and development (R&D) expenditure guidance updated to US$230 million to US$270 million, enabled by the Company’s strong commercial performance and the non-refundable payment of US$40 million received from Regeneron. Q2 2026 Revenue Revenue (US$M) Q2 2026 Q2 2025 % Change Q1 2026 % Change Group revenue 247 204 21% 230 7% Precision Medicine revenue 5 202 155 30% 186 9% TMS revenue 6 45 48 (6)% 44 2% Executive Commentary ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA 7 imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix's market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses. We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value.” Therapeutics Business Unit Telix continues to progress its industry-leading Therapeutics pipeline, which spans multiple product candidates and disease areas. Q2 2026 highlights include: TLX591-Tx (lutetium ( 177 Lu) rosopatamab tetraxetan): Achieved key regulatory milestone for ProstACT Global Phase 3 trial, with the FDA confirming that the safety data from Part 1 of the study of Telix's lead prostate cancer therapy candidate is sufficient to enable progression of Part 2 in the U.S. The FDA and Telix also achieved alignment on the Part 2 clinical trial protocol, statistical analysis plan, and ongoing safety monitoring plan. Initiation of Part 2 in the U.S. remains subject to the FDA’s review of an Investigational New Drug (IND) amendment 8 . Part 2 continues to enroll strongly in regions where recruitment is open including Australia, New Zealand, Canada, Türkiye, the United Kingdom, Singapore and South Korea and has also received regulatory approval to commence in China. TLX597-Tx ( 177 Lu-DOTA-HYNIC-panPSMA): OPTIMAL-PSMA study evaluating TLX597-Tx for mCRPC has recently completed patient enrollment of 120 patients 9 . Building on initial findings of the OPTIMAL-PSMA study, the first patients have been dosed in the OPTIMAL-e Phase 2 study, evaluating TLX597-Tx for metastatic hormone sensitive prostate cancer 10 . TLX597-Tx is a next generation small molecule PSMA-targeting prostate cancer radioligand therapy (RLT) candidate designed to improve efficacy and quality of life in earlier-stage metastatic prostate cancer. TLX250-Tx (lutetium ( 177 Lu) girentuximab tetraxetan): Dosed first patient in LUTEON 11 , a pivotal trial of TLX250-Tx as a monotherapy in advanced ccRCC 12 . LUTEON will evaluate the efficacy of TLX250-Tx compared with investigator’s choice of monotherapy consistent with standard of care. LUTEON forms part of Telix’s global development program 13 for TLX250-Tx, Part 1 is expected to enroll up to 40 patients. TLX101-Tx ( 131 I-iodofalan): Enrolled first patient cohort in Part 1 (assessing safety and dose optimization) of IPAX BrIGHT, an international, multi-center pivotal trial of TLX101-Tx in patients with recurrent glioblastoma 14 . The trial is open for enrollment in Australia, Austria, the Netherlands and Belgium, with approval being sought in additional jurisdictions. Completed patient enrollment in IPAX-2 15 , a Phase 1 study evaluating TLX101-Tx in patients with newly diagnosed glioblastoma, with no dose-limiting toxicities observed to date 16 . Precision Medicine Business Unit PSMA imaging portfolio: Telix's Precision Medicine business continues to expand its commercial reach and support broader patient access to PSMA-PET/CT imaging 17 . Q2 2026 highlights include: Rapid enrollment of 338 patients in BiPASS™ Phase 3 study of Illuccix and Gozellix for the initial diagnosis of prostate cancer, integrating non-invasive 68 Ga-PSMA-11 PET imaging prior to biopsy. Building on the clinical foundation established by the PRIMARY 18 and PRIMARY 2 19 studies, BiPASS™ is intended to support regulatory submissions in major markets, including the U.S., Europe and Australia. Completed patient enrollment in Japan in Phase 3 registrational study of TLX591-Px (Illuccix) 20 . Telix is preparing a New Drug Application (NDA) for submission in Japan, with clinical data from the Phase 3 local study intended to support the application. In parallel, Telix's application for Conditional Approval is under review by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). If granted, Conditional Approval will enable an expedited NDA review process while the final study clinical dataset is prepared. TLX101-Px, (Floretyrosine F 18 or 18F-FET) for brain cancer imaging: Submitted an IND application to the FDA for Pixclara ® , a Phase 3 registrational study for indication expansion for the diagnosis of brain metastases. The FDA has accepted Telix's resubmitted NDA for Pixclara ®21 and has granted a PDUFA 22 goal date of September 11, 2026 23 . Telix's Marketing Authorization Application (MAA) for Pixlumi ®21 in Europe has been validated and accepted for review 24 . Zircaix ® 21 (TLX250-Px, 89 Zr-DFO-girentuximab) for kidney cancer imaging: Telix continues to make good progress on its Biologics License Application (BLA) resubmission for Zircaix ®21 in the U.S. Final Chemistry, Manufacturing and Controls (CMC) documentation is nearing completion. Consistent with TLX250-Px’s Breakthrough Therapy designation, Telix has maintained regular consultation with the FDA and expects to resubmit the application shortly. Telix Manufacturing Solutions (TMS): Expanded global operations TMS continues to expand its global operations which are fundamental to Telix's future growth, supporting supply chain resilience. Q2 2026 highlights include: Opened TMS North Melbourne, in partnership with the Melbourne Theranostic Innovation Centre (MTIC) 25 . The purpose-built facility combines radiochemistry laboratories, clinical product manufacturing, patient dosing and imaging that aims to provide advanced clinical infrastructure and R&D capabilities to accelerate the development of targeted radiopharmaceuticals. TMS Brussels South successfully completed its first Good Manufacturing Practice (GMP) production run of a lutetium-based therapeutic candidate, representing a significant operational milestone and further validating the facility's capabilities to support the manufacture of Telix's next-generation therapeutics. Installed ARTMS' QUANTM ® Irradiation System (QIS ® ) at TMS Yokohama, expanding isotope production capabilities and enabling local Zirconium-89 ( 89 Zr) manufacturing to support Telix's portfolio. The installation represents further progress in scaling the ARTMS network and advancing toward the Company's target of 50 QIS ® installations globally by the end of 2026. Corporate Updates Telix entered into a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies 26 . The strategic partnership combines Telix’s radiopharmaceutical development, manufacturing and supply chain capabilities with Regeneron’s leading antibody discovery and development platforms, creating a framework to advance multiple novel oncology programs and further strengthen Telix’s position in Precision Medicine. On execution of the agreement, Telix has received an initial non-refundable payment from Regeneron of US$40 million. Telix also completed a refinancing of its existing convertible bond structure, issuing US$600 million of new convertible bonds due 2031 and repurchasing all outstanding 2029 convertible bonds 27 . The transaction extends debt maturities, enhances financial flexibility and further strengthens the Company’s capital structure, supporting the execution of Telix’s long-term growth strategy, including developing its late-stage therapeutics pipeline. Three new Non-Executive Directors were appointed during the quarter as part of Telix's Board expansion and succession planning. Effective May 11, 2026, David Gill, Maria Rivas, MD, and William Jellison 28 joined the Board, further strengthening the Board's clinical, commercial, financial and governance expertise, enhancing the Company's capabilities as a dual-listed, commercial stage biopharmaceutical company. FY 2026 guidance Telix expects FY 2026 revenue and other income to be in excess of US$1 billion, with revenue tracking in line with the upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million non-refundable other income from Regeneron. Revenue guidance reflects product sales in jurisdictions with a marketing authorization, and a full year of revenue contribution from RLS. Telix has updated FY 2026 R&D expenditure guidance to US$230 million to US$270 million, subject to achieving ongoing global clinical data outcomes and development milestones. The additional investment will support the advancement of high-value clinical programs beyond the Company's original R&D forecast, including acceleration of the TLX597-Tx program and label expansion for Pixclara ® , and progression of the Regeneron strategic collaboration. About Telix Pharmaceuticals Limited Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. Telix's commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix ® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S. and Gozellix ® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. FDA. No other Telix product mentioned in this announcement has received a marketing authorization in any jurisdiction. The Company's late-stage therapeutic pipeline includes three assets in pivotal-stage trials - TLX591-Tx (lutetium-177 ( 177 Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx ( 131 I-iodofalan) in recurrent glioblastoma, TLX250-Tx (lutetium ( 177 Lu) girentuximab tetraxetan) in kidney cancer, complemented by a deep pipeline of next generation assets. Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit or follow Telix on LinkedIn , X and Facebook . Investor Relations Annie Kasparian Annie.kasparian@telixpharma.com Charlene Jaw Charlene.jaw@telixpharma.com Media Eliza Schleifstein Eliza@schleifsteinpr.com This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Guidance Disclaimer The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below. Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions. Legal Notices Cautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. ©2026 Telix Pharmaceuticals Limited. All rights reserved. 1 The financial information for the quarter ended June 30, 2026 is unaudited. 2 Metastatic castration-resistant prostate cancer. 3 Telix ASX disclosure July 2, 2026. ClinicalTrials.gov ID: NCT06520345 . 4 ClinicalTrials.gov ID: NCT07052214 . 5 Primarily sales of Illuccix and Gozellix in our Precision Medicine business. 6 Telix Manufacturing Solutions (TMS) third-party revenue predominantly driven by RLS Radiopharmacies (RLS), excludes Illuccix and Gozellix sales and TMS inter-segment revenue. 7 Prostate-specific membrane antigen. 8 Telix ASX disclosure July 2, 2026. 9 Telix LinkedIn June 25, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437 . 10 Telix media release July 16, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336 . 11 Telix media release July 21, 2026. ClinicalTrials.gov ID: NCT07197580 . 12 Clear cell renal cell carcinoma. 13 Telix’s global development program for TLX250-Tx includes the separate LUTEON ATLAS study in the U.S. and Europe. 14 ClinicalTrials.gov ID: NCT07100730 . 15 ClinicalTrials.gov ID: NCT05450744 . 16 Telix media release May 19, 2026. 17 Imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography. 18 Emmett et al. Eur Urol. 2021. 19 Buteau et al. Lancet Oncol. 2026. ClinicalTrials.gov ID: NCT05154162 . 20 Telix media release July 17, 2026. Japan Registry of Clinical Trials identifier: JRCT2031250473. 21 Brand name subject to final regulatory approval. 22 Prescription Drug User Fee Act. 23 Telix ASX disclosure April 10, 2026. 24 Telix media release May 1, 2026. 25 Telix media release July 16, 2026. 26 Telix ASX disclosure April 13, 2026. 27 Telix ASX disclosure April 23, 2026. 28 Telix ASX disclosure April 2, 2026. Telix ASX disclosure April 9, 2026.

Phase I dose escalation study with pamlectabart tismanitin (HDP-101) in multiple myeloma completed Dose escalation study has started at the recommended Phase II dose (RP2D) and is proceeding as planned Amendment of existing agreement with HealthCare Royalty and participation of Soleus Capital; payment of USD 20 million extends cash reach to mid-2027 Partnered ADC programs with Takeda and Huadong are progressing successfully; milestone payments received from both parties Peter Willinger appointed new Chief Financial Officer Financial figures in line with planning Ladenburg, Germany, 15 July 2026 - Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today published its financial report on the first six months of 2026 (1 December 2025 - 31 May 2026) and reported on the course of business. Dr. Dongzhou Jeffery Liu, Chief Executive Officer of Heidelberg Pharma, commented: "Following the structural adjustments that became necessary at the end of 2025, we are pleased to report a successful first half of the year. We have reached several important milestones from both financial and clinical development perspectives. The Phase I dose escalation study of our lead candidate, pamlectabart tismanitin, which included a total of ten treated cohorts, has been completed, and the Recommended Phase II dose (RP2D) has been established. We have already initiated the clinical Phase IIa part of the study, and in total 16 patients are currently included in the Phase IIa trial.” Peter Willinger, Chief Financial Officer of Heidelberg Pharma, added: “We also significantly strengthened our financial situation. In addition to milestone payments received from our partners Takeda and Huadong, the amended licensing agreement with HealthCare Royalty and Soleus Capital secured us with further significant funding and extended our cash reach through mid-2027. Together with the restructuring measures implemented and consistent cost management, this has created greater financial stability and planning security for the Company. Recently, our shareholders approved the reduction of the Supervisory Board from seven to five members at the Annual General Meeting, reflecting the Company’s adjusted corporate structure. As a result, Dr. Birgit Kudlek and Dr. Georg F. Baur will step down from the Supervisory Board at the end of July 2026. Dr. Baur has served on the Supervisory Board since 2000 and Dr. Kudlek since 2012. On behalf of the Management Board and Supervisory Board, I would like to express our sincere gratitude to both of them for their many years of dedicated service and valuable support. At the same time, we welcome Jack Yefei Ling, who took over the seat of Dr. Dongzhou Jeffery Liu.” Milestone payment from partner Takeda received: Partner Takeda has started clinical development of its ADC candidate, which utilizes the Amanitin-based ADC technology licensed from Heidelberg Pharma. With the dosing of the first patient in a Phase I/II clinical trial in patients with solid tumors, an agreed-upon development milestone was reached at the end of 2025, triggering a payment to Heidelberg Pharma. Financial details were not disclosed. Amendment to existing license agreement with HealthCare Royalty secures USD 20 million: In early March, a further amendment to the existing license agreement with HealthCare Royalty (HCRx), with the participation of Soleus Capital Management, L.P. (Soleus Capital), was signed. The amended agreement covers the partial monetization of Heidelberg Pharma’s future royalty payments from the global sale of Telix’s diagnostic imaging agent TLX250-Px (proposed trade name: Zircaix). In connection with the amendment, Heidelberg Pharma received USD 20 million from Soleus Capital upfront. As part of the current contract extension, Heidelberg Pharma has agreed to an increase in the cap on total payments as well as certain other contractual amendments. Soleus Capital’s participation has no impact on the payment from HCRx upon FDA approval. Milestone payment from partner Huadong received: Strategic development partner Huadong dosed the first patient in a clinical trial with pamlectabart tismanitin in China in March, hereby achieving an agreed-upon development milestone that triggered a payment to Heidelberg Pharma. The Phase I clinical trial will evaluate the safety, tolerability, pharmacokinetics and efficacy of pamlectabart tismanitin in the Chinese patient population with plasma cell disorders including multiple myeloma. This bridging study is conducted in addition to the existing clinical program with this ATAC to ensure comparability of safety and efficacy across different populations. Dosing has been initiated at 140 µg/kg, a dose level previously shown to be safe and well tolerated in the Caucasian ethnicity. As of the end of June 2026, the first cohort has been completed and dosing in the second cohort has started. New preclinical data from the ATAC technology platform presented at the AACR 2026 Annual Meeting: Heidelberg Pharma presented promising preclinical data from its Amanitin-based ADC HDP-103 targeting metastatic castration‑resistant prostate cancer (mCRPC) at the American Association for Cancer Research (AACR) Annual Meeting 2026 in April 2026. HDP-103 demonstrates target specific binding in human tissues and robust and durable antitumor activity in patient-derived xenograft (PDX) models. The potent anti-tumor efficacy of HDP-103, combined with a favorable half-life and a manageable safety profile, leads to a comfortable therapeutic index (TI) of HDP-103 that is well in the range of other ADCs that are approved or in development for solid tumor indications. Taken together, these data warrant further clinical development of HDP-103 as a novel treatment option for mCRPC. The poster is available on the company's website.[1] Start of the Phase IIa part with Recommended Phase II Dose of pamlectabart tismanitin (HDP-101): The ATAC candidate pamlectabart tismanitin, an Amanitin-based ADC candidate targeting BCMA, is being evaluated in a Phase I/IIa clinical trial for the treatment of relapsed or refractory multiple myeloma. In early April, the Phase I part of the study was completed and the recommended dose for the Phase IIa part of the study (Recommended Phase 2 Dose; RP2D) was determined. At that time, the ninth cohort at a dose of 175 µg/kg and the tenth cohort at a dose level of 218 µg/kg had been completed, with patient evaluation ongoing. Heidelberg Pharma’s Benefit-and-Risk-Assessment Team followed the recommendation of the Safety Review Committee (SRC), which had comprehensively reviewed the safety, tolerability, and pharmacokinetic (PK) data from the ongoing Phase I study, in determining the RP2D. The Phase IIa part of the study has already started and is progressing as planned. A total of 16 patients is currently included at RP2D, with additional patients in the screening process. Change in Executive Management Board: Heidelberg Pharma announced in April 2026 that its Chief Financial Officer, Walter Miller, will leave the company at his own request upon the expiration of his contract to pursue new professional opportunities. Mr. Peter Willinger assumed the role of Chief Financial Officer effective 1 May 2026. The Heidelberg Pharma Group, consisting of Heidelberg Pharma AG as well as its subsidiaries Heidelberg Pharma Research GmbH, HDP G250 AG & Co. KG and HDP G250 Beteiligungs GmbH, reports consolidated figures. The two latter companies are not operationally active and affiliated with the parent company, like Heidelberg Pharma Research GmbH. The reporting period covers the period from 1 December 2025 to 31 May 2026 (H1 2026). The Heidelberg Pharma Group generated sales revenue and income of EUR 9.2 million in the first six months of the 2026 financial year (previous year: EUR 5.0 million), representing an increase of 84%. Sales revenue totaled EUR 7.4 million and mainly consisted of milestone payments and sales of materials (previous year: EUR 1.4 million). Other income, at EUR 1.8 million, was significantly lower than the previous year's level of EUR 3.6 million, which had been primarily driven by a milestone payment related to a prior minority stake sale. Due to the reduction of the research department and additional cost-saving measures, operating expenses, including depreciation and amortization, decreased to EUR 12.3 million in the reporting period (previous year: EUR 18.0 million), representing a decrease of 32%. Cost of sales comprises the Group's costs directly related to sales revenue. These mainly include expenses for the supply of Amanitin linker material to license partners. In line with the increase in revenue, cost of sales was significantly above the previous year's level, amounting to EUR 0.7 million (previous year: EUR 0.1 million), and corresponded to 6% of operating expenses. Research and development costs fell from EUR 13.5 million in the previous year to EUR 8.3 million, due to the restructuring program. The previous year was marked by higher costs for the ongoing clinical trial with pamlectabart tismanitin as well as the start of the second clinical trial with HDP-102. This category continued to represent the largest cost item, accounting for 67% of operating expenses. Administrative expenses, including costs for holding activities and the stock exchange listing, amounted to EUR 2.8 million (previous year: EUR 3.4 million) and accounted for 23% of operating expenses. Other expenses for business development, marketing and commercial market supply activities decreased to EUR 0.5 million (previous year: EUR 1.0 million) and accounted for 4% of operating expenses. The Heidelberg Pharma Group's net loss for the first six months of 2026 amounted to EUR 3.4 million (previous year: EUR 12.6 million). The significantly lower loss is attributable to both higher sales and lower expenses. Earnings per share amounted to EUR -0.07 and, taking into account the average number of shares in the comparative period, improved in line with the net income for the period compared with the previous year (EUR -0.27). As of 31 May 2026, Heidelberg Pharma had cash of EUR 24.9 million (30 November 2025: EUR 15.0 million; 31 May 2025: EUR 33.3 million). Taking into account the impact on cash of exchange rate and other effects, the total net cash inflow amounted to EUR 10.0 million (previous year: EUR 3.8 million). Total assets as of 31 May 2026 amounted to EUR 46.9 million, up from EUR 38.1 million as of the 30 November 2025 reporting date. The Group’s Equity at the end of the reporting period amounted to EUR -14.2 million (30 November 2025: EUR -10.9 million) and corresponded to an equity ratio of -30.3% (30 November 2025: -28.6%). Heidelberg Pharma’s focus remains on pamlectabart tismanitin for the treatment of relapsed or refractory multiple myeloma. The goal is to complete patient enrollment for the Phase IIa portion in the third or fourth quarter of 2026. At the same time, partner Huadong is continuing the ongoing Phase I bridging study in China and is already preparing for further clinical development in a Phase II study. In addition, both companies are working on other projects to explore the potential of the ATAC technology in additional indications. The remaining development programs are available for partnerships. Furthermore, the partner Telix Pharmaceuticals plans to resubmit the marketing authorization application for TLX250-Px and is advancing the clinical development of the TLX250-Tx therapeutic program. The full-year financial guidance issued on 26 March 2026 for the Heidelberg Pharma Group is confirmed. The financing is secured until mid-2027 based on current internal planning. Financial outlook Actual 2025 guidance 2026 EUR million Sales revenue and other income 6.9 11.0 – 15.0 Operating expenses (49.0) (25.0) – (29.0) Operating result (42.1) (13.0) - (17.0) Change in cash funds, total 1 (14.4) (0.0) – (4.0) Cash balance at the end of the fiscal year 2 15.0 11.0 – 15.0 1 Not including any corporate actions 2 Excluding exchange rate effects between the euro and foreign currencies H1 2026 1 EUR thsd. H1 2025 1 EUR thsd. Earnings Sales revenue 7,377 1,389 Other income 1,852 3,575 Operating expenses (12,330) (18,024) of which research and development costs (8,339) (13,452) Operating result (3,101) (13,060) Earnings before tax (2,987) (12,591) Net loss for the period (3,413) (12,591) Earnings per share in EUR (0.07) (0.27) Balance sheet as of the end of the period Total assets 46,895 62,455 Cash 24,930 33,255 Equity (14,219) 18,519 Equity ratio2 in % (30.3) 29.7 Cash flow statement Cash flow from operating activities (7,313) (14,112) Cash flow from investing activities 685 (80) Cash flow from financing activities 16,687 18,025 Cash flow from other activities (105) 0.5 Employees (number) Employees as of the end of the period3 42 122 Full-time equivalents as of the end of the period3 41 111 1 The reporting period begins on 1 December and ends on 31 May 2 Equity / total assets 3 Including members of the Executive Management Board Rounding of exact figures may result in differences. The full half-yearly financial report, including the consolidated financial statements prepared in accordance with International Financial Reporting Standards (IFRS), was published at http://heidelberg-pharma.com/en/press-and-investors/announcements/financial-reports. There will be no conference call on the half-year report. [1] https://heidelberg-pharma.com/en/research-development/scientific-posters